Sign up
Pharma Capital

Summit Therapeutics chief hails potential of drug that treats fatal childhood disease

“The strength of the interim data from our PhaseOut DMD trial has bolstered our belief that ezutromid could become a new standard of care for all patients with Duchenne muscular dystrophy,” said boss Glyn Edwards
boy walking a boardwalk
Duchenne muscular dystrophy is a fatal muscle-wasting disease that affects boys

Summit Therapeutics PLC (LON:SUMM, NASDAQ:SMMT) chief executive Glyn Edwards believes the company’s phase II drug could be the new standard of care for children with Duchenne muscular dystrophy, a fatal muscle-wasting disease that affects boys.

His assessment of the potential of ezutromid followed the release of 24-week data from the company’s clinical study of the treatment, which revealed a statistically significant and meaningful reduction in both muscle damage and inflammation.

READ: Summit Therapeutics discovers new potential antibiotics for gonorrhoea

“The strength of the interim data from our PhaseOut DMD trial has bolstered our belief that ezutromid could become a new standard of care for all patients with Duchenne muscular dystrophy,” Edwards said in an update alongside the company’s first-quarter results.

The read-out from the completed second-phase trial is expected in the third-quarter.

The company’s second drug, next-generation antibiotic ridinilazole, is expected to undergo a phase III trial in the first three months of next year.

Financially, Summit is in a strong position. A £15mln share placing helped bolster Summit’s bank balance, which was £27.7mln at the end of April. The company posted a loss of £5.8mln for the three months ended April 30.

 

Ian_55ae0ddd437b7.jpg
Why Invest In Summit Therapeutics PLC? Read More Here

Register here to be notified of future SUMM Company articles
View full SUMM profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.